Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study

Heun, R.; Sliwka, U.; Rüttinger, H.; Schimrigk, K.

Journal of Neurology 239(1): 31-35

1992


ISSN/ISBN: 0340-5354
PMID: 1541966
DOI: 10.1007/bf00839208
Accession: 007483442

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Fifty patients with multiple sclerosis were treated either by corticosteroids given systemically or by intrathecal injection of a steroid crystal suspension. Before and 3 weeks after the beginning of the treatment we examined the patients according to the Expanded Disability Status Scale (EDSS). Four patients had to be excluded from evaluation. In 23 patients the examination revealed at least a small improvement in their disability status. There were 7 intrathecally and 5 systemically treated patients whose disability was significantly reduced. One patient under intrathecal treatment showed a minor deterioration in disability. There was no clear difference in the frequency of improved symptoms or in EDSS scores between the two therapies.

Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study